All AbMole products are for research use only, cannot be used for human consumption.
LY2157299 (Galunisertib) could inhibit TGF-β-mediated SMAD2 activation and hematopoietic suppression in primary hematopoietic stem cells. Furthermore, administration of LY2157299 ameliorated anemia in a TGF-β overexpressing transgenic mouse model of bone marrow failure in vivo. LY2157299 also shows dose dependent potentiation of VEGF or bFGF induced cell proliferation in HUVEC. LY2157299 blocked the phsophorylation of Smad2 but had no effect on fibroblast growth factor (FGF) or platelet-derived growth factor (PDGF) signaling. In the in vitro VEGF-stimulated cord formation assay, LY2157299 potentiates angiogenesis. LY2157299 induces angiogenesis and enhances VEGF and basic-fibroblast-growth-factor-induced angiogenesis in a Matrigel-plug assay, whereas adding an alpha5-integrin-neutralizing antibody to the Matrigel selectively inhibits this enhanced response.
Composites Part B. 2023 Feb 15;110487.
Construction of tissue-engineered vascular grafts with high patency by mimicking immune stealth and blocking TGF-β mediated endothelial-to-mesenchymal transition
LY2157299 (Galunisertib) purchased from AbMole
EMBO Mol Med. 2019 Aug;11(8):e9830.
An autocrine ActivinB mechanism drives TGFβ/Activin signaling in Group 3 medulloblastoma.
LY2157299 (Galunisertib) purchased from AbMole
 |
Source | Universite Paris-Sud (2014). Figure 6. LY2157299 (Abmole Bioscience) |
| Method | Flow cytometry | |
| Cell Lines | IGR-CaP1 and IGR-CaP1-R cells | |
| Concentrations | 25 μM | |
| Incubation Time | 72 h | |
| Results | "Our results show that the targeting of the TGFβ signaling pathway with LY2157299 in combination with Docetaxel induces cell death of the Docetaxel-resistant cells." |
 |
Source | Universite Paris-Sud (2014). Figure 5. LY2157299 (Abmole Bioscience) |
| Method | Clonogenicity assay | |
| Cell Lines | IGR-CaP1 and IGR-CaP1-R cells | |
| Concentrations | 25 μM | |
| Incubation Time | 72 h | |
| Results | Figure 5A shows that treatment of cells with 25μM of LY2157299 alone did not affect the survival of parental and resistant cells. |
| Cell Experiment | |
|---|---|
| Cell lines | HCC cell |
| Preparation method | HCC cells were incubated in serum-free medium overnight and treated with 5 ng/mL of TGF-β for 1 hour followed by the addition of 1 or 10 μM galunisertib for 5 and 24 hours. Concentrations were selected to be in the range of observed plasma exposure |
| Concentrations | 1 or 10 µM |
| Incubation time | 5 and 24 h |
| Animal Experiment | |
|---|---|
| Animal models | Sprague-Dawley male rats |
| Formulation | 0.9% NaCl water |
| Dosages | 75 mg/kg/day |
| Administration | intragastrically |
| Molecular Weight | 369.42 |
| Formula | C22H19N5O |
| CAS Number | 700874-72-2 |
| Solubility (25°C) | DMSO 80 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related TGF-β Receptor Products |
|---|
| CJJ300
CJJ300 is a transforming growth factor-β (TGF-β) inhibitor with an IC50 of 5.3 µM. |
| AZ12601011
AZ12601011 is an orally active, selective TGFBR1 kinase inhibitor with an IC50 of 18 nM and a Kd of 2.9 nM. |
| TGF-βRI inhibitor 1
TGF-βRI inhibitor 1 (compoimd i) is a TGF-βRI inhibitor. |
| TGF-βRI inhibitor 1 methylbenzenesulfonate
TGF-βRI inhibitor 1 (compoimd i) methylbenzenesulfonate is a TGF-βRI inhibitor. |
| LSKL TFA
LSKL TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
